The European AIDS Clinical Society (EACS) is a not-for-profit group of European physicians, clinicians and researchers in the field of HIV / AIDS

It aims to bring together scientists from all over Europe to help exchange the latest medical and scientific knowledge regarding clinical aspects of HIV/ AIDS and its complications.

**Executive Committee Members:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Reiss</td>
<td>President</td>
<td>Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>Manuel Battegay</td>
<td>Vice President</td>
<td>Basel, Switzerland</td>
</tr>
<tr>
<td>Nathan Clumeck</td>
<td>Treasurer</td>
<td>Brussels, Belgium</td>
</tr>
<tr>
<td>Fiona Mulcahy</td>
<td>Secretary</td>
<td>Dublin, Ireland</td>
</tr>
<tr>
<td>José Arribas</td>
<td></td>
<td>Madrid, Spain</td>
</tr>
<tr>
<td>Antonella d'Arminio Monforte</td>
<td></td>
<td>Milan, Italy</td>
</tr>
<tr>
<td>抗炎peace Gattell</td>
<td></td>
<td>Barcelona, Spain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anna-Maria Geretti</td>
<td></td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>Christine Katlama</td>
<td></td>
<td>Paris, France</td>
</tr>
<tr>
<td>Jens Lundgren</td>
<td></td>
<td>Copenhagen, Denmark</td>
</tr>
<tr>
<td>Anton Pozniak</td>
<td></td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>Jürgen Rockstroh</td>
<td></td>
<td>Bonn, Germany</td>
</tr>
<tr>
<td>Mike Youle</td>
<td></td>
<td>London, United Kingdom</td>
</tr>
</tbody>
</table>

**PANEL MEMBERS**

- Nathan Clumeck, Chair, Brussels, Belgium
- Anton Pozniak, London, United Kingdom
- François Raffi, Nantes, France
The European AIDS Clinical Society (EACS) is a not-for-profit group of European physicians, clinicians and researchers in the field of HIV / AIDS

It aims to bring together scientists from all over Europe to help exchange the latest medical and scientific knowledge regarding clinical aspects of HIV/ AIDS and its complications.

**Executive Committee Members:**

Peter Reiss, President  
Amsterdam, The Netherlands

Manuel Battegay, Vice President  
Basel, Switzerland

Nathan Clumeck, Treasurer  
Brussels, Belgium

Fiona Mulcahy, Secretary  
Dublin, Ireland

José Arribas  
Madrid, Spain

Antonella d’Arminio Monforte,  
Milan, Italy

José Gatell  
Barcelona, Spain

Anna-Maria Geretti  
London, United Kingdom

Christine Katlama  
Paris, France

Jens Lundgren  
Copenhagen, Denmark

Anton Pozniak  
London, United Kingdom

Jürgen Rockstroh  
Bonn, Germany

Mike Youle  
London, United Kingdom

**PANEL MEMBERS**

Nathan Clumeck  
Chair, Brussels, Belgium

Anton Pozniak  
London, United Kingdom

François Raffi  
Nantes, France
Assessment Of HIV Infected Patients

Initial visit

- Complete medical history
- Physical examination, including height, weight, BMI, blood pressure
- Laboratory evaluation
  - Confirmation of HIV antibody positive
  - Plasma HIV RNA
  - Resistance testing (genotype) with determination of HIV subtype
  - CD4 absolute count + percentage (optional: CD8 and %)
  - Complete blood count, AST, ALT, Alk phosphatase, calcium phosphate, glucose, creatinine, calculated creatinine clearance
  - Antibody tests for toxoplasma, CMV, Hepatitis A, B and C, and syphilis
  - Fasting blood glucose and lipids including fasting total LDL & HDL cholesterol, and triglycerides (see metabolic guidelines)
  - Urine dipstick for protein and sugar

- HLA B*5701 determination (if available)
- Sexually Transmitted Infection screen if appropriate
- Women: cervical pap smear
- Assessment of social and psychological condition: provide support and counselling if needed
- Consider HAV and HBV vaccination (depending on serology results) and pneumococcal vaccination
- PPD if CD4 above 400. Negative PPD does not exclude active or latent tuberculosis

Subsequent visits

(Asymptomatic patients not receiving antiretroviral therapy)

- At least every 6 months
  - Complete blood count, CD4 count and %, plasma HIV RNA

- Every year
  - Physical examination
  - Evaluation of social and psychological support, smoking cessation
  - Repeat serologic testing (syphilis, CMV, toxoplasmosis, hepatitis B, hepatitis C) if previously negative
  - AST, ALT
  - Women: cervical pap smear
  - If cirrhosis (regardless of cause): alphafeto protein + ultrasound examination
  - Fasting lipids

Treatment initiation

- Assess and support patients'readiness to start combined ART (see specific guidelines)
- Physical examination, including height, weight, BMI, blood pressure
- Plasma HIV RNA
- Resistance testing (genotype), if not yet obtained
- CD4 count and % (optional: CD8 count and %)
- Complete blood count, AST, ALT, bilirubin, creatinine, calculated creatinine clearance
- Fasting glucose and lipids

Visits on therapy

- Plasma HIV RNA
- CD4 count and % (optional: CD8 count and %)
- Complete blood count, creatinine, calculated creatinine clearance, AST, ALT bilirubin
- Other laboratory parameters according to selected regimen
- Fasting glucose and lipids
New table “Assessing and supporting patients’ readiness to start cART” (1)

Goal: Facilitate decision making and starting cART for patients who qualify according to international guidelines.

Before initiating cART, screen for decision making and adherence barriers:

<table>
<thead>
<tr>
<th>Patient related factors:</th>
<th>System related factors:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A) Depression (2)</td>
<td>E) Health insurance and drug supply</td>
</tr>
<tr>
<td>B) Harmful alcohol or recreational drug use (3)</td>
<td>F) Continuity of drug supply</td>
</tr>
<tr>
<td>C) Cognitive problems (4)</td>
<td>G) Social support and disclosure</td>
</tr>
<tr>
<td>D) Low health literacy.</td>
<td></td>
</tr>
</tbody>
</table>

Recognise, discuss and reduce problems wherever possible!

Assess patients’ readiness and support progress between stages (5):

“I would like to talk about HIV-medication” <wait> “what do you think about it?” (6)

Remember:

Precontemplation:
“I don’t need it, I feel good”
“I don’t want to think about it”

Support: Show respect for patient attitude / Try to understand health and therapy beliefs / Establish trust / Provide individualised short information / Schedule the next appointment.

Contemplation:
“I am weighing things up and feel torn about what to do about it”

Support: Allow ambivalence / Support to weigh pros and cons together with patient / Assess information needs and support information seeking / Schedule the next appointment.

Preparation
“I want to start, I think the drugs will allow me to live a normal life”

Support: Reinforce decision / Make shared decision on most convenient regimen / Educate: adherence, resistance, side effects / Discuss integration into daily life / Assess self-efficacy

Ask: “Do you think you can manage to take cART consistently once you have started?”

Use: VAS 0-10 (8)

Consider skills training:
- Medication-taking training, possibly MEMS (2-4wk) (9)
- Directly Observed Therapy with educational support
- Use aids: Pill boxes, cell phone alarm, involve contact persons where appropriate

Patients presenting in the clinic may be at different stages of readiness: Precontemplation, contemplation or preparation [Trans-theoretic model; Prochaska JO. Am Psychol 47:1102-1114, 1992]. The first step is to assess this stage, and then to support/intervene accordingly. An exception is if a patient presents late or very late, i.e. <200 or <50 CD4/µl. In this case the initiation of cART should not be delayed; the clinician should try to identify the most important adherence barriers which may be present, and support the patient to be prepared for prompt initiation of cART.

Screen: For adherence problems in each meeting (10)
Support: Discuss side effects, educate about surrogate markers, discuss integration of drug taking schedule
Empower: Give positive feedback

START and maintain adherence
This table should facilitate the initiation of cART. Matters for consideration listed in this table, such as decision making or barriers to adherence, have to be judged clinically in their context. For instance the clinician has to judge whether cART has to be initiated immediately despite the detection of possible barriers to adherence or whether delaying initiation is justified. Consider patient's cultural background.

2 Ask: “During the past month have you often been bothered by feeling down, depressed or hopeless?” “During the past month have you often been bothered by little interest or pleasure in doing things?” “Is this something with which you would like help?” If answers are positive, then sensitivity is 96%, specificity 89% (Arroll B et al. BMJ 327:1144-1146. 2003).

3 Ask: “Have you thought about Cutting down?” “Have you ever become Annoyed when people talk to you about your drinking?” “Have you ever felt Guilty about your drinking?” “Do you ever have a drink first thing in the morning (Eye opener)?” An affirmative answer to more than two CAGE-questions means a sensitivity and specificity for problematic alcohol use of more than 90% (Kitchens JM. JAMA 272(22):1782-1787. 1994.). Ask similar questions for recreational drug use.

4 Ask: “Do you feel that you are having problems concentrating in your daily life?” “Do you feel slow in your thinking?” “Do you feel that you are having problems with your memory?” “Have relatives or friends expressed that they feel you are having problems with your memory or difficulty concentrating?”

5 Patients presenting in the clinic may be at different stages of readiness: Precontemplation, contemplation or preparation [ Transtheoretic model ; Prochaska JO. Am Psychol 47:1102-1114, 1992]. The first step is to assess this stage, and then to support/intervene accordingly. An exception is if a patient presents late or very late, i.e. <200 or <50 CD4/µl. In this case the initiation of cART should not be delayed; the clinician should try to identify the most important adherence barriers which may be present, and support the patient to be prepared for prompt initiation of cART.

6 This is a suggested opening question to assess the patient's stage of readiness. Further discussion will indicate which of the three initial stages the patient has reached: he/she might even be ready for therapy.


8 VAS (= Visual Analogue Scale; Range from 0 to 10 i.e. 0 = I will not manage, 10 = I am sure I will manage).

9 Medication training/ MEMS training could be done with vitamins before starting cART.

10 Suggested adherence questions: “In the past 4 wks how often have you missed a dose of your HIV medication: every day, more than once a wk, once a wk, once every 2 wks, once a month, never?” “Have you missed more than one dose in a row?” (Glass TR et al. Antiviral Therapy 13(1):77-85. 2008).

Primary HIV infection (PHI)

**Definition of Acute primary HIV infection**
- High risk exposure within previous 2-8 weeks,
- and Clinical symptoms,
- and detectable HIV in the plasma (p24 Ag and/or HIV RNA > 10 000 c/ml)
- and negative or indeterminate serologic testing (negative or weakly positive ELISA, and WB ≤ 1 band)
- Recommendation: confirm HIV infection by HIV antibody test (WB) performed 3-6 weeks later.

**Treatment:**
- Favour clinical trial
- Treatment indicated if:
  - AIDS defining events
  - confirmed CD4 <350/mm³ at month 3 or beyond
- Treatment should be considered if
  - Severe illness/prolonged symptoms (especially CNS symptoms)
- Treatment optional, as indication relies only on theoretical considerations. In most situations, wait till month

6 (with CD4 and plasma HIV-RNA monitoring) and follow criteria for initiation of treatment in chronic HIV infection. Some experts recommend treatment as a tool for prevention of HIV transmission.

Duration of treatment: unknown but maybe should be lifelong. Maintain closer follow-up in case of treatment interruption

**Resistance testing:**
- Recommended in all situations as soon as acute HIV infection is diagnosed, even if treatment not initiated
- In case it cannot be performed, store blood for further testing.

**Transmission:**
- Recognize sexually transmitted infections (STIs), including syphilis, gonorrhoea, Chlamydia (Urethritis and LGV), HPV, hepatitis B and hepatitis C.
- Counsel newly diagnosed patient on high risk of transmission and preventive measures (condoms) including notifying and testing partners.

* If treatment of PHI is considered then patients should be recruited into on-going clinical trials
# Recommendations for Initiation of Therapy in Naïve HIV-Infected Patients

<table>
<thead>
<tr>
<th>Symptomatic</th>
<th>Asymptomatic</th>
<th>Resistance testing</th>
<th>Additional remarks</th>
</tr>
</thead>
</table>
| **● CDC stage B and C: treatment recommended.**<br>**● If OI, initiate as soon as possible*** | **● CD4 < 200: Treatment recommended, without delay.**<br>**● CD4 201-350: treatment recommended.**<br>**● CD4 350-500: treatment may be offered if VL>10⁵ c/ml and/or CD4 decline >50-100/mm³/year or age >55 or hepatitis C co-infection**<br>**● CD4 > 500: treatment should be deferred, independently of Plasma HIV RNA; closer follow-up of CD4 if VL > 10⁵ c/ml.**<br>Whatever CD4 and Plasma HIV RNA, treatment can be offered on an individual basis, especially if patient seeking and ready for ARV therapy | Genotypic testing and subtype determination recommended, ideally at the time of HIV diagnosis, otherwise before initiation of first-line regimen<br>**If genotypic testing is not available, a ritonavir-boosted PI could be preferred in the first-line regimen** | **● Before starting treatment, CD4 should be repeated and confirmed**<br>**● Time should be taken to prepare the patient, in order to optimize compliance and adherence** **

* Pay particular attention to drug-drug interactions, drug toxicities, immune reconstitution syndrome and adherence, etc…
** See recommendation on “Assessing and supporting patients readiness to start cART
### Initial Combination Regimen for Antiretroviral-Naïve patient

<table>
<thead>
<tr>
<th>Select 1 drug in column A and 1 NRTI combination in column B</th>
<th>A</th>
<th>B</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Recommended</strong></td>
<td></td>
<td>ABC/3TC²-³ (*)&amp; TDF/FTC</td>
<td></td>
</tr>
<tr>
<td>NNRTI</td>
<td></td>
<td>ABC/3TC co-formulated</td>
<td></td>
</tr>
<tr>
<td>• EFV¹</td>
<td></td>
<td>TDF/FTC co-formulated</td>
<td></td>
</tr>
<tr>
<td>• NVP⁴</td>
<td></td>
<td>fAPV/r: 700/100 mg bid</td>
<td></td>
</tr>
<tr>
<td>or ritonavir-boosted PI</td>
<td></td>
<td>or 1400/200 mg qd</td>
<td></td>
</tr>
<tr>
<td>• FPV/r</td>
<td></td>
<td>LPV/r: 400/100 mg bid</td>
<td></td>
</tr>
<tr>
<td>• LPV/r**</td>
<td></td>
<td>or 800/200 mg qd</td>
<td></td>
</tr>
<tr>
<td>• SQV/r</td>
<td></td>
<td>SQV/r: 1000/100 mg bid</td>
<td></td>
</tr>
<tr>
<td>• ATV/r</td>
<td></td>
<td>or 1500/100 mg qd or</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2000/100 mg qd</td>
<td></td>
</tr>
<tr>
<td><strong>Alternative</strong></td>
<td>DRV/r⁵</td>
<td>ZDV/3TC⁶</td>
<td>ZDV/3TC co-formulated</td>
</tr>
<tr>
<td>or ritonavir-boosted PI</td>
<td></td>
<td>ddI/3TC or FTC⁶</td>
<td></td>
</tr>
</tbody>
</table>

---

1. **EFV**: not recommended in pregnant women or women with no reliable and consistent contraception; not active on HIV-2 and HIV-1 group O
2. Contra-indicated if HLA B*5701 positive. Even if HLA B*5701 negative, counselling on HSR risk still mandatory
3. ABC + NVP contra-indicated, unless HLA B*5701 negative
4. NVP: Use with extreme caution in women with CD4 >250 and men with CD4 >400/µL; not active on HIV-2 and HIV-1 group O
5. Not yet approved by either FDA or EMEA. However, once this is the case DRV/r may be added to the list of recommended boosted PI's for initial treatment
6. Only if unavailable or intolerant to other recommended NRTIs

* Abacavir should be used with caution in patients with a high cardiovascular risk and/or patients with more than 100,000 copies/ml.

** ACTG 5142, randomised study showed lower virological efficacy of LPV/r vs EFV. However no PI mutations were seen in the LPV/r failures.
### Virological Failure

<table>
<thead>
<tr>
<th>Definition</th>
<th>Confirmed Plasma HIV RNA &gt; 50 copies/ml 6 months after starting therapy (initiation or modification) in patients that remain on ART</th>
</tr>
</thead>
</table>
| General measures | - Evaluate adherence, compliance, tolerability, drug-drug interactions, drug-food interactions, psychosocial issues  
- Perform resistance testing on failing therapy (usually reliable with plasma HIV RNA levels >500-1000 copies/ml) and obtain historical resistance testing for archived mutations  
- Consider TDM  
- Review antiretroviral history  
- Identify treatment options, active, potentially active drugs/combinations |
| Management of virological failure (VF) | If Plasma HIV RNA > 50 and <500-1000 copies/ml  
- Check for adherence  
- Check Plasma HIV RNA 1 to 2 months later  
- Improve boosted PI's PK (if applicable)  
If Plasma HIV RNA confirmed > 500/1000 copies/ml, change regimen as soon as possible: what to change will depend on the resistance testing results:  
- No resistance mutations found: re-check for adherence, perform TDM  
- Resistance mutations found: switch to a suppressive regimen based on drug history; multidisciplinary experts discussion advised  
Goal of new regimen: Plasma HIV RNA < 400 c/ml after 3 months, Plasma HIV RNA < 50 c/ml after 6 months |
| In case of resistance mutations demonstrated | General recommendations:  
- Use 2 or preferably 3 active drugs in the new regimen (including active drugs from previously used classes)  
- Any regimen should use at least 1 drug from a class not used previously e.g. fusion, integrase or CCR inhibitor (if tropism test shows R5 virus only)  
- Defer change if < 2 active drugs available, based on resistance data, except in patients with low CD4 count (<100/mm³) or with high risk of clinical deterioration for whom the goal is the preservation of immune function through partial reduction of Plasma HIV RNA (> 1 log reduction) by recycling.  
- If limited options, consider experimental and new mechanistic drugs, favouring clinical trials (but avoid functional monotherapy)  
- Treatment interruption is not recommended  
Optimisation of new regimen:  
- Avoid NNRTI in NNRTI-experienced patients; Etravirine potentially active in selected NNRTI-resistance profiles  
- Consider continuation of 3TC or FTC even if documented resistance mutation (M184V/I)  
- Select other potentially active NRTI(s), on treatment history and full resistance (past and present) evaluation  
- Select 1 active ritonavir-boosted PI. If at all possible avoid double boosted PIs  
- Always check for drug-drug-interactions, and when necessary perform TDM of drugs of new regimen if available  
If many options are available, criteria of preferred choice include: simplicity of the regimen, toxicity risks evaluation, drug-drug-interactions, future salvage therapy |
Pregnant women should be monitored every month and as close as possible to the predicted delivery date.

<table>
<thead>
<tr>
<th>Criteria for starting ART in pregnant women (see different scenarios)</th>
<th>Same as for non pregnant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Objective of treatment in pregnant women</td>
<td>Full Plasma HIV RNA suppression by third trimester and specifically at time of delivery</td>
</tr>
<tr>
<td>Resistance testing</td>
<td>Same as for non pregnant, i.e. before starting ART and in case of virological failure</td>
</tr>
</tbody>
</table>

**SCENARIO**

1. Women becoming pregnant while already on ART
2. Women becoming pregnant while treatment naïve and who fulfil the criteria (CD4) for initiation of ART
3. Women becoming pregnant while treatment naïve and who do not fulfil the criteria (CD4) for initiation of ART
4. Women whose follow up starts after W28 of pregnancy

- 1. Maintain ART but switch drugs that are potentially teratogenic
- 2. Start ART at start of 2nd trimester is optimal
- 3. Start ART at start of W28 of pregnancy (at the latest 12 weeks before delivery); start earlier if high plasma viral load or risk of prematurity
- 4. Start ART immediately

**Antiretroviral regimen in pregnancy**

Same as non pregnant,
- Except avoid EFV
- ABC, NVP and TDF not to be initiated but continuation is possible if started before pregnancy
- Among PI/r, prefer LPV/r or SQV/r
- ZDV should be part of the regimen if possible

**Drugs contra-indicated during pregnancy**

Efavirenz, ddI + d4T, Triple NRTI combinations

**IV zidovudine during labour**

Benefit uncertain if Plasma HIV RNA < 50 c/ml

**Single dose nevirapine during labour**

Not recommended

**Caesarean section**

Indicated except if Plasma HIV RNA < 50 c/ml at W34-36
## Post-Exposure Prophylaxis (PEP)

### POST-EXPOSURE PROPHYLAXIS (PEP) RECOMMENDED IF

<table>
<thead>
<tr>
<th>Nature of exposure</th>
<th>Status of source patient</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood</strong></td>
<td></td>
</tr>
<tr>
<td>Subcutaneous or intramuscular penetration with IV or IM needle, or intravascular device</td>
<td>HIV + Or serostatus unknown but presence of HIV risk factors</td>
</tr>
<tr>
<td>• Percutaneous injury with sharp instrument (lancet), IM or SC needle, suture needle</td>
<td>HIV +</td>
</tr>
<tr>
<td>• Contact &gt; 15 min of mucous membrane or non intact skin</td>
<td></td>
</tr>
<tr>
<td><strong>Genital secretions</strong></td>
<td>HIV + Or serostatus unknown but presence of HIV risk factors</td>
</tr>
<tr>
<td>Anal or vaginal sex</td>
<td></td>
</tr>
<tr>
<td>Receptive oral sex with ejaculation</td>
<td>HIV +</td>
</tr>
<tr>
<td><strong>Intravenous drug user</strong></td>
<td>HIV +</td>
</tr>
<tr>
<td>Exchange of syringe, needle, preparation material or any other material</td>
<td></td>
</tr>
</tbody>
</table>

**Management and Treatment of HIV**

- Rapid testing of the source patient for HCV and HIV (if HIV status unknown) recommended,
- If source patient HIV+ on ARV therapy, order genotyping testing if HIV-RNA > 1000 copies/µL
- PEP to be started ideally < 4 hours after the exposure, and no later than 48 hours
- Duration of PEP: 4 weeks
- PEP regimen: TDF/FTC (alternative: ZDV/3TC) + either LPV/r tablets 400/100 mg bid or SQV/r 1000/100 mg bid
- Full sexual health screen in case of sexual exposure
- Follow-up:
  - HIV serology + HBV and HCV, pregnancy test (women) within 48 hours of exposure
  - Reevaluation of PEP indication by HIV expert within 4-72 hours
- Assess tolerability of ARV PEP regimen
- Transaminases, HCV-PCR and HCV serology at month 1 if source of exposure were HCV+ (observed or suspected)
- Repeat HIV serology after 2 and 4 months, syphilis serology after 1 month if sexual exposure